Eremopetasinorone A

Details

Top
Internal ID f3fc02d0-0cb3-4205-ab0a-457816f6a2ad
Taxonomy Organic oxygen compounds > Organooxygen compounds > Carbonyl compounds > Cyclic ketones
IUPAC Name (3aR,4R,7aR)-2-acetyl-3a,4-dimethyl-4,6,7,7a-tetrahydro-1H-inden-5-one
SMILES (Canonical) CC1C(=O)CCC2C1(C=C(C2)C(=O)C)C
SMILES (Isomeric) C[C@H]1C(=O)CC[C@H]2[C@@]1(C=C(C2)C(=O)C)C
InChI InChI=1S/C13H18O2/c1-8-12(15)5-4-11-6-10(9(2)14)7-13(8,11)3/h7-8,11H,4-6H2,1-3H3/t8-,11+,13+/m0/s1
InChI Key JJZRURWGJILXRH-RLCGTCKNSA-N
Popularity 0 references in papers

Physical and Chemical Properties

Top
Molecular Formula C13H18O2
Molecular Weight 206.28 g/mol
Exact Mass 206.130679813 g/mol
Topological Polar Surface Area (TPSA) 34.10 Ų
XlogP 1.80
Atomic LogP (AlogP) 2.53
H-Bond Acceptor 2
H-Bond Donor 0
Rotatable Bonds 1

Synonyms

Top
CHEBI:168727
DTXSID801145916
(3aR,4R,7aR)-2-acetyl-3a,4-dimethyl-4,6,7,7a-tetrahydro-1H-inden-5-one
(3aR,4R,7aR)-2-Acetyl-1,3a,4,6,7,7a-hexahydro-3a,4-dimethyl-5H-inden-5-one
182127-76-0

2D Structure

Top
2D Structure of Eremopetasinorone A

3D Structure

Top

ADMET Properties (via admetSAR 2)

Top
Target Value Probability (raw) Probability (%)
Human Intestinal Absorption + 0.9971 99.71%
Caco-2 + 0.8546 85.46%
Blood Brain Barrier + 0.8250 82.50%
Human oral bioavailability - 0.5143 51.43%
Subcellular localzation Mitochondria 0.6369 63.69%
OATP2B1 inhibitior - 0.8489 84.89%
OATP1B1 inhibitior + 0.9139 91.39%
OATP1B3 inhibitior + 0.9669 96.69%
MATE1 inhibitior - 0.8000 80.00%
OCT2 inhibitior - 0.5750 57.50%
BSEP inhibitior - 0.8803 88.03%
P-glycoprotein inhibitior - 0.9481 94.81%
P-glycoprotein substrate - 0.8483 84.83%
CYP3A4 substrate + 0.5258 52.58%
CYP2C9 substrate - 1.0000 100.00%
CYP2D6 substrate - 0.8495 84.95%
CYP3A4 inhibition - 0.7708 77.08%
CYP2C9 inhibition - 0.9318 93.18%
CYP2C19 inhibition - 0.8097 80.97%
CYP2D6 inhibition - 0.9345 93.45%
CYP1A2 inhibition - 0.8014 80.14%
CYP2C8 inhibition - 0.9385 93.85%
CYP inhibitory promiscuity - 0.8516 85.16%
UGT catelyzed - 0.0000 0.00%
Carcinogenicity (binary) - 0.9500 95.00%
Carcinogenicity (trinary) Non-required 0.4893 48.93%
Eye corrosion - 0.9692 96.92%
Eye irritation - 0.6416 64.16%
Skin irritation + 0.7025 70.25%
Skin corrosion - 0.9476 94.76%
Ames mutagenesis - 0.7528 75.28%
Human Ether-a-go-go-Related Gene inhibition - 0.4829 48.29%
Micronuclear - 0.8800 88.00%
Hepatotoxicity + 0.6908 69.08%
skin sensitisation + 0.8101 81.01%
Respiratory toxicity - 0.6444 64.44%
Reproductive toxicity + 0.6222 62.22%
Mitochondrial toxicity + 0.6375 63.75%
Nephrotoxicity + 0.4563 45.63%
Acute Oral Toxicity (c) III 0.6447 64.47%
Estrogen receptor binding - 0.7778 77.78%
Androgen receptor binding - 0.5730 57.30%
Thyroid receptor binding - 0.7806 78.06%
Glucocorticoid receptor binding - 0.8073 80.73%
Aromatase binding - 0.6770 67.70%
PPAR gamma - 0.8439 84.39%
Honey bee toxicity - 0.9242 92.42%
Biodegradation + 0.5250 52.50%
Crustacea aquatic toxicity - 0.5900 59.00%
Fish aquatic toxicity + 0.9189 91.89%

Targets

Top

Proven Targets:

CHEMBL ID UniProt ID Name Min activity Assay type Source
No proven targets yet!

Predicted Targets (via Super-PRED):

CHEMBL ID UniProt ID Name Probability Model accuracy
CHEMBL3251 P19838 Nuclear factor NF-kappa-B p105 subunit 95.28% 96.09%
CHEMBL5619 P27695 DNA-(apurinic or apyrimidinic site) lyase 91.34% 91.11%
CHEMBL2581 P07339 Cathepsin D 88.46% 98.95%
CHEMBL340 P08684 Cytochrome P450 3A4 86.08% 91.19%
CHEMBL253 P34972 Cannabinoid CB2 receptor 85.42% 97.25%
CHEMBL241 Q14432 Phosphodiesterase 3A 85.07% 92.94%
CHEMBL1994 P08235 Mineralocorticoid receptor 84.06% 100.00%
CHEMBL3137262 O60341 LSD1/CoREST complex 82.39% 97.09%
CHEMBL3108638 O15164 Transcription intermediary factor 1-alpha 82.27% 95.56%
CHEMBL4040 P28482 MAP kinase ERK2 80.38% 83.82%
CHEMBL1806 P11388 DNA topoisomerase II alpha 80.29% 89.00%

Cross-Links

Top
PubChem 10584415
NPASS NPC150628
LOTUS LTS0136386
wikiData Q105130078